RETEVMO dosage is meticulously determined by patient age and body weight or body surface area, with specific adjustments required for concomitant medications, hepatic impairment, and management of adverse reactions.

Dosing and Administration Protocols

The recommended dosage of RETEVMO for adults and adolescents (12 years and older) is weight-based: 120 mg orally twice daily for those less than 50 kg, and 160 mg orally twice daily for those 50 kg or greater. For pediatric patients aged 2 to less than 12 years, dosing is based on body surface area (BSA), ranging from 40 mg three times daily (0.33-0.65 m²) to 160 mg twice daily (≥1.53 m²). RETEVMO can be taken with or without food, unless coadministered with a proton pump inhibitor (PPI), in which case it should be taken with food. Dose modifications are crucial when used with acid-reducing agents (PPIs, H2 antagonists, antacids) or strong/moderate CYP3A inhibitors, which generally necessitate a dose reduction. Patients with severe hepatic impairment also require a reduced RETEVMO dosage. Dose adjustments, including reductions or discontinuation, are outlined for various adverse reactions.